DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas

Phase 2

Completed

Conditions: Glioma

Interventions: Biological: PEG-interferon alfa-2b
Drug: Thalidomide

First Posted Date: 2002-10-23

Last Posted Date: 2011-10-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 7

Registration Number: NCT00047879

Locations: 🇺🇸
National Institutes of Health, Bethesda, Maryland, United States

Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum

Completed

Conditions: Basal Cell Carcinoma
Xeroderma Pigmentosum
Squamous Cell Carcinoma
Skin Cancer
Melanoma

First Posted Date: 2002-09-23

Last Posted Date: 2024-01-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 301

Registration Number: NCT00046189

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: F-18 Fluorodeoxyglucose
Biological: therapeutic allogeneic lymphocytes
Procedure: Peripheral Blood Stem Cell donation
Drug: cyclophosphamide
Drug: cyclosporine
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: fludarabine phosphate
Drug: melphalan
Drug: prednisone
Drug: sirolimus
Drug: tacrolimus
Drug: vincristine sulfate
Procedure: peripheral blood stem cell transplantation
Drug: Filgrastim

First Posted Date: 2002-08-16

Last Posted Date: 2017-05-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00043979

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Collection of Blood, Bone Marrow, Tumor or Tissue Samples

Completed

Conditions: Precancerous Conditions
Neoplasms

First Posted Date: 2002-08-12

Last Posted Date: 2017-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 74

Registration Number: NCT00043615

Locations: 🇺🇸
National Naval Medical Center, Bethesda, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk

Completed

Conditions: Ovarian Cancer
Breast Cancer

First Posted Date: 2002-08-09

Last Posted Date: 2025-05-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00043472

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Treatment of Binge Eating Disorder

Not Applicable

Completed

Conditions: Binge Eating Disorder

First Posted Date: 2002-07-17

Last Posted Date: 2010-01-13

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 200

Registration Number: NCT00041743

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

Sirolimus for Focal Segmental Glomerulosclerosis

Phase 2

Completed

Conditions: Focal Glomerulosclerosis

First Posted Date: 2002-06-27

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 30

Registration Number: NCT00040508

Locations: 🇺🇸
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States

Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer

Phase 2

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Amifostine trihydrate
Radiation: Radiation therapy

First Posted Date: 2002-06-26

Last Posted Date: 2012-04-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00040365

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma

Recruiting

Conditions: Melanoma
Dysplastic Nevus Syndrome

First Posted Date: 2002-06-26

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3000

Registration Number: NCT00040352

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

Completed

Conditions: Familial Ovarian Cancer
Familial Breast Cancer
BRCA2-associated Malignancies
BRCA1-associate Malignancies

First Posted Date: 2002-06-24

Last Posted Date: 2025-03-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 377

Registration Number: NCT00040222

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy